FORMULATION OPTIMIZATION FOR COLON TARGETED DELIVERY OF KATIRA GUM MATRIX TABLETS CONTAINING AZATHIOPRINE
Abstract
Katira gum, a natural polysaccharide resembles guar gum in chemical composition and is susceptible to degradation by colonic microflora. Azathioprine is used in the treatment of inflammatory bowel disease, ulcerative colitis and Crohn’s disease. Present investigation was undertaken to design Katira gum oral colon targeted matrix tablets containing azathioprine, in order to maximize its therapeutic efficacy. Central composite design (software design expert v. 8.0.7.1) was employed to optimize the formulation for maximum drug release in colon. The optimized batch tablets obtained were further coated by Eudragit S100 to minimize the drug release in upper part of GIT. The uncoated matrix tablets released around 20-50% of the drug in the physiological environment of stomach and small intestine but released all its contents in the colon. The coated optimized formulation exhibited a release of only 5-35% in stomach and small intestine and almost all drug in simulated colonic dissolution media. The drug release kinetics followed Korsmeyer-Peppas model, indicating the drug release mechanism through combined diffusion and erosion mechanism. The results suggested that Katira gum can be a good carrier for colon targeting owing to its moderate viscosity, biocompatibility and biodegradability which could be successfully degraded by the microbial flora in the colon.
Keywords:
Azathioprine, Katira gum, central composite design, colon targeting, matrix tabletsDOI
https://doi.org/10.25004/IJPSDR.2013.050401References
2. Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G, Molteni F. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol. 1997; 25:330-333.
3. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: Benefits outweigh the risk of lymphoma. Gastroenterol. 2000; 118:1018-1024.
4. Van den Mooter G, Kinget R. Oral colon-specific drug delivery- A review. Drug Deliv. 1995; 2:81-93.
5. Ojha AK, Maiti D, Chandra K, Mondal S, Das D, Roy SK, Ghosh K, Islam SS. Structural assignment of a heteropolysaccharide isolated from the gum of Cochlospermum religiosum (Katira Gum). Carbohydr Res. 2008; 343:1222-1231.
6. Chaurasia M, Chourasia MK, Jain NK, Jain A, Soni V, Gupta Y, Jain SK. Cross-linked guar gum microspheres: A viable approach for improved delivery of anticancer drugs for the treatment of colorectal cancer. AAPS Pharm Sci Tech. 2006; 7:E143-151.
7. Alvarez-Mancenido F, Landin M, Martinez-Pacheco R. Konjac glucomannan/xanthan gum enzyme sensitive binary mixtures for colonic drug delivery. Eur J Pharm Biopharm. 2008; 69:573-581.
8. Rajera R, Nagpal K, Singh SK, Mishra DN. Toxicological study of the Primaquine phosphate loaded chitosan nanoparticles in mice. Int J Biol Macromol. 2013; 62:18-24.
9. Bharaniraja B, Kumar KJ, Prasad CM, Sen AK. Different approaches of Katira gum formulations for colon targeting. Int J Biol Macromol. 2011; 49:305-310.
10. Gauri B, Nagpal L, Singh SK. Formulation and Gamma Scintigraphic Evaluation of Colon targeted drug delivery systems of tinidazole in healthy human volunteers. J Pharm Biomed Sci. 2011; 7:1-9.
11. Sinha VR, Mittal BR, Kumria R. In-vivo evaluation of time and site of disintegration of polysaccharide tablet prepared for colon-specific drug delivery. Int J Pharm. 2005; 289:79-85.
12. Purushothaman M, Vijaya RJ. Formulation optimization and release kinetics of tinidazole matrix, compression and spray coated tablets: effect of organic acid on colon targeted drug delivery systems. JITPS. 2010; 1:18-32.
13. Banker GS, Anderson NR. The Theory and Practice of Industrial Pharmacy. Edn 3, Varghese Publishing House, Bombay, 1987, pp. 296-302.
Published
Abstract Display: 284 
PDF Downloads: 352 
